Richard Greil

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial”.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30321-1

N/A

5.7DataRank · unranked

527 citations

Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle +14 more

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

The Lancet Oncology(2023)10.1016/s1470-2045(23)00344-3

N/A

3.1DataRank · unranked

105 citations

Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo +20 more

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00925

N/A

0.520DataRank · unranked

31 citations

Gilles Salles, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný +32 more

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients

Annals of Hematology(2011)10.1007/s00277-011-1192-5

N/A

0.330DataRank · unranked

8 citations

Michael Fiegl, Florian Falkner, Michael Steurer, Niklas Zojer, Georg Hopfinger +9 more

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Blood Advances(2025)10.1182/bloodadvances.2025017144

N/A

0.165DataRank · unranked

2 citations

Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil +11 more

1530P Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

Annals of Oncology(2020)10.1016/j.annonc.2020.08.2013

N/A

0DataRank · unranked

0 citations

Florian Posch, Lena Horvath, Antonia Gantschnigg, Felix Renneberg, Esther Schwarzenbacher +11 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity

Haematologica(2020)10.3324/haematol.2019.231944

N/A

0DataRank · unranked

42 citations

Elisabeth Bayer, Xiaobing Yu, Julia M. Laufer, Jan Philip Höpner, Suzana Tesanovic +20 more